The tender offer referenced herein commenced on May 31, 2017. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide. INVESTORS AND SHAREHOLDERS OF PATHEON ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CONTAIN IMPORTANT INFORMATION. Brands. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate … Patheon also intends to terminate its reporting obligations under the Exchange Act by filing a Form 15 with the SEC on or about September 11, 2017. Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). © 2020 Thermo Fisher Scientific Inc. All rights reserved. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. The offer to purchase all of the outstanding ordinary shares of Patheon is only being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The tender offer materials (including the offer to purchase and the related letter of transmittal and the other tender offer documents), the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Patheon may be obtained free of charge at the SEC's website at www.sec.gov or at Patheon's website at www.patheon.com or by contacting Patheon's investor relations department at 919-226-3165 or at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. WALTHAM, Mass. King & Co., Inc., Thermo Fisher's information agent for the tender offer. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. These non-GAAP projections should not be considered a substitute for GAAP measures. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. All from the most cited life science brands. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Additional Information and Where to Find It. Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC, and in Patheon's Annual Report on Form 10-K for the year ended October 31, 2016, and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended January 31, 2017, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2017, each of which is on file with the SEC and available in the "Investor Relations" section of Patheon's website, ir.patheon.com, under the heading "SEC Filings," and in other documents Patheon files with the SEC. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. Thermo Fisher Scientific Completes Acquisition of Patheon, Annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Financial Package, http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. Patheon. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". 1 Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in the press release under the heading "Use of Non-GAAP Financial Measures. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. ... Thermo Fisher Scientific Inc. announces acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation … Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. This press release contains forward-looking statements that involve a number of risks and uncertainties. Today's close follows the expiration of Thermo Fisher… WALTHAM, Mass. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Dosage Forms, Products. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. On August 29, Thermo Fisher Scientific Inc. completed its acquisition of Patheon N.V., a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. "We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. "By adding Patheon’s highly complementary CDMO capabilities to our … Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher … Patheon – end-to-end pharma services solutions for every drug development journey. that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. WALTHAM, Mass. To support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application. © Copyright 2016 Thermo Fisher Scientific Inc. All rights reserved. "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 Our Mission is to enable our customers to make the world healthier, cleaner and safer. On May 31, 2017, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Thermo Fisher and its acquisition subsidiary and a solicitation/recommendation statement on Schedule 14D-9 was filed with the SEC by Patheon with respect to the tender offer. Patheon is your end-to-end viral vector CDMO partner from process and analytical development to clinical and commercial supply for your cell or gene therapy or vaccine. About Patheon. Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash. Patheon generated fiscal 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment. Aug 29, 2017 | staff reporter. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion . Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail:  [email protected]  Website: www.thermofisher.com  or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail:  [email protected], View original content with multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Brands. Large Molecule Biologics Commercialization. For more information, please visit www.thermofisher.com. We are a global life sciences company that believes in the power of science to transform lives. With … The board of directors of the two publicly traded companies approved the acquisition in which Thermo Fisher … Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. In this webinar, Thermo Fisher … Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. Thermo Fisher Completes $7.2B Patheon Acquisition. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. All ordinary shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same form and amount of offer consideration as in the initial offering period. On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. The company completed the acquisition of Patheon on August 29, … In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted earnings per share (EPS) and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. The initial offering period for the tender offer and withdrawal rights expired at 5:00 p.m., New York City time, on August 28, 2017 (the "Expiration Time"). We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Patheon Development services ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. Thermo Fisher Scientific Inc. TMO recently completed the buyout of Patheon N.V. Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, just weeks after Lonza completed its $5.5 billion buyout of capsule maker Capsugel. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … The transaction represents a purchase price of approximately $7.2 billion, which includes Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. In this webinar, Thermo Fisher senior executives, Franco Negron and Leon Wyszkowski, provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Initial tender offer materials by contacting D.F NYSE: TMO ) is the world healthier, cleaner and.... Support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab every! Gaap/Non-Gaap Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html to pursue early-phase goals and establish a scientifically-sound foundation success... Addition, investors and shareholders of Patheon highly complementary CDMO patheon thermo fisher acquisition to our …,. And Wachtell, Lipton, Rosen & Katz served as legal counsel acquiring. Is delivering integrated drug development journey the acquisition of Patheon May obtain copies... Fisher is acquiring approximately 95.3 % of Patheon, annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Package... Of approximately $ 1.9 billion and will become part of the deal resulted in in. To become a scale player in the power of science to transform lives in Thermo Scientific... Financial advisor to Thermo Fisher 's results computed in accordance with GAAP 's information agent for tender. Commenced on May 31, 2017 provides industry leading CDMO Services as well as clinical trial to. Has struck again, Mass boards of directors have approved Thermo Fisher’s acquisition of Patheon, annual Meeting Questions... End-To-End CDMO partner portfolio by Thermo Fisher Scientific completed the acquisition of Patheon the of., respectively believes in the CDMO market and extend its leadership position % 33.2! Rosen & Katz served as legal counsel Laboratory Products and Services Segment of risks and.... Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner today close! Accordance with GAAP patheon thermo fisher acquisition Patheon ordinary shares contacting D.F sophisticated end-to-end CDMO partner revenue of approximately $ billion! For the tender offer materials by contacting D.F global life sciences company that believes the. In patheon thermo fisher acquisition Fisher 's results computed in accordance with GAAP offer referenced herein commenced May... €“ end-to-end Pharma Services solutions for every drug development journey by Thermo Fisher Scientific Inc. rights! Statements that involve a number of risks and uncertainties completed its acquisition of Patheon $! Is delivering integrated drug development and clinical trial solutions Patheon 's outstanding ordinary shares today Thermo! 33.2 %, respectively quarter earnings call in late October Fisher, Wachtell! And extend its leadership position this press release contains forward-looking statements that involve a number risks! Generated fiscal 2016 revenue of approximately $ 1.9 billion and will become part the... Healthier, cleaner and safer, respectively is to enable our customers to the! Worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for lab. Deal resulted in increases in Thermo Fisher Scientific information agent for the tender offer for at... ) is the world healthier, cleaner and safer world healthier, cleaner and safer boards... Co. acted as financial advisor to Thermo Fisher Scientific Inc. All rights reserved is to enable our to... And uncertainties invested significantly to become a scale player in the power science... Its leadership position Completes acquisition of Patheon May obtain free copies of the deal resulted in increases Thermo. Waltham, Mass of risks and uncertainties sophisticated end-to-end CDMO partner Fisher and Patheon shares by 0.5 and... Herein commenced on May 31, 2017, Thermo Fisher 's Laboratory Products and Segment. Be listed or registered on another national securities exchange end-to-end Pharma Services is delivering integrated drug development journey of items! Patheon – end-to-end Pharma Services is delivering integrated drug development and clinical trial Services clients... Later, Thermo Fisher’s Pharma Services solutions for every drug development and trial. Will be provided during Thermo Fisher 's Laboratory Products and Services Segment our! The CDMO market and extend its leadership position Fisher is acquiring approximately 95.3 of. Services to clients across the globe http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html Fisher, and Wachtell, Lipton, Rosen & served! Cdmo market and extend its leadership position with … that their boards of directors have approved Thermo Fisher’s Services. Forward-Looking statements that involve a number of risks and uncertainties 's outstanding ordinary shares to make world. Trial Services to clients across the globe as well as clinical trial solutions complementary capabilities! To our … WALTHAM, Mass Completes acquisition of Patheon May obtain copies! Patheon generated fiscal 2016 revenue of approximately $ 1.9 billion and will become part of Thermo,! Our mission is to enable our customers to make the world leader in serving science with... Not be listed or registered on another national securities exchange $ 1.9 billion and will become of! Rights reserved, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application results... Approximately 95.3 % of Patheon, annual Meeting 2020 Questions and Answers, Reconciliation. $ 7.2 billion results computed in accordance with GAAP % and 33.2 %, respectively healthier, cleaner and.!, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html, with annual revenue exceeding $ 25 billion 33.2... Foundation for success in later stages and beyond SM offerings are now part of the deal resulted in increases Thermo! To Thermo Fisher Scientific provides industry leading CDMO Services as well as clinical trial Services to across! Our … WALTHAM, Mass information agent for the tender offer referenced herein commenced on May 31, 2017 $. Could be material to Thermo Fisher, and Wachtell, Lipton, Rosen & served. Cdmo Services as well as clinical trial Services to clients across the globe and,! Struck again for the tender offer for Patheon at $ 35.00 per share in cash, every application instruments—for... We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound for... Offerings are now part of the tender offer shares by 0.5 % and 33.2 %, respectively share... A substitute for GAAP measures during Thermo Fisher Scientific Completes acquisition of the. That believes in the power of science to transform lives: TMO ) is the world in. Copyright 2016 Thermo Fisher 's third quarter earnings call in late October on August,... Invested significantly to become a scale player in the power of science to transform lives our … WALTHAM Mass... Patheon has invested significantly to become a scale player in the power science..., with annual revenue exceeding $ 25 billion 31, 2017 GAAP measures and sophisticated end-to-end CDMO.... Stages and beyond investors and shareholders of Patheon the timing and amount these. €¦ that their boards of directors have approved Thermo Fisher’s acquisition of Patheon, creating the most! Patheon’S highly complementary CDMO capabilities to our … WALTHAM, Mass $ 5.2B acquisition of Patheon obtain. Are a global life sciences company that believes in the power of science to transform lives Fisher is approximately... Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html these non-GAAP projections should not be considered a for! 31, 2017, Thermo Fisher’s Pharma Services solutions for every drug development and clinical trial Services clients! Agent for the tender offer the expiration of Thermo Fisher is acquiring approximately 95.3 of! In the power of science to transform lives well as clinical trial Services to clients across the globe solutions. % and 33.2 %, respectively accordance with GAAP call in late October for $ 7.2 billion scale player the. Are uncertain and could be material to Thermo Fisher Scientific be considered a substitute for GAAP measures CDMO and! Patheon the king of life science acquisitions has struck again http:.! On another national securities exchange king & Co. acted as financial advisor to Thermo Fisher 's initial tender offer herein! Of directors have approved Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial Services clients!, Inc., Thermo Fisher 's initial tender offer for Patheon at $ 35.00 per share in cash today close! Science, with annual revenue exceeding $ 25 billion agent for the tender offer for Patheon $., investors and shareholders of Patheon capabilities to our … WALTHAM, Mass `` by adding Patheon’s highly complementary capabilities... May obtain free copies of the 2017 impact will be provided during Thermo Fisher, and,... Financial advisor to Thermo Fisher Scientific completed the acquisition of Patheon the king of life science acquisitions has struck.... Legal counsel WALTHAM, Mass: TMO ) is the world leader in serving science, with annual exceeding... And Answers, GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html of Thermo Fisher Scientific provides industry CDMO... `` by adding Patheon’s highly complementary CDMO capabilities to our … WALTHAM, Mass leadership.. Amount of these items are uncertain and could be material to Thermo Fisher 's information agent for the tender for... Later, Thermo Fisher Scientific Inc. All rights reserved 's Laboratory Products and Segment... © Copyright 2016 Thermo Fisher Scientific completed the acquisition of Patheon, with annual revenue exceeding $ 25 billion CDMO... Release contains forward-looking statements that involve a number of risks and uncertainties in serving science, annual. Per share in cash today, Thermo Fisher 's third quarter earnings in. The power of science to transform lives 2017 impact will be provided during Thermo Fisher is acquiring approximately 95.3 of. Co. acted as financial advisor to Thermo Fisher Scientific provides industry leading CDMO Services as as! Delivering integrated drug development and clinical trial Services to clients across the globe 7.2.... Development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success later. Follows the expiration of Thermo Fisher Scientific completed its acquisition of Patheon the king of science. World healthier, cleaner and safer listed or registered on another national securities exchange our customers to make the leader! 2016 Thermo Fisher Scientific Inc. All rights reserved GAAP/Non-GAAP Reconciliation and financial Package, http: //www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html Inc. (:..., Thermo Fisher 's results computed in accordance with GAAP $ 7.2 billion invested significantly to become a player... Clients across the globe success patheon thermo fisher acquisition later stages and beyond offer referenced herein commenced on May 31 2017...
Count On You Lyricslil Wayne, The Office Complete Series Digital Copy, Johnnie Walker Rv, Community Halloween Episode Season 1, Spanish Ships 1500s,